Daré Bioscience to Participate in Three February Conferences
Daré Bioscience, a leader in women’s health innovation, announced participation in key February conferences. CEO Sabrina Martucci Johnson will present at the 2023 BIO CEO & Investor Conference from February 6-9, with a presentation scheduled for February 7 at 3:00 p.m. EST. The company will also be involved in the virtual SVB Securities Global Biopharma Conference from February 13-16, and Johnson will join a panel at the Women’s Health Innovation Series in Boston on February 16 at 3:30 p.m. EST. Daré focuses on advancing innovative products in women’s health, including contraceptives and treatments for sexual health disorders.
- None.
- None.
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in the following February conferences:
2023 BIO CEO & Investor Conference
February 6-9, 2023, New York Marriott Marquis, New York, NY
Company presentation: Tuesday, February 7th at 3:00 p.m. EST
Ms. Johnson will be available for one-on-one meetings.
SVB Securities Global Biopharma Conference
February 13-16, 2023, Virtual
Members of the company’s management team will be available for one-on-one meetings.
3rd Annual Women’s Health Innovation Series: Reproductive Health Innovation Summit
February 15-16, 2023, Boston Park Plaza, Boston, MA
Panel Presentation: Contraception: Traversing the Lesser-Known Male Space Thursday, February 16th at 3:30 p.m. EST Moderator: Heather Vahdat, Executive Director, Male Contraceptive Initiative Kevin Eisenfrats, Co-Founder & CEO, Contraline Stasia Obremskey, Managing Director, RH Capital Sabrina Martucci Johnson, President & CEO, Daré Bioscience Akash Bakshi, CEO, YourChoice Therapeutics |
About Daré Bioscience
Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, vaginal, and reproductive, menopause, and sexual health.
Daré’s first FDA-approved product, XACIATOTM (clindamycin phosphate) vaginal gel,
Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:
Lee Roth
Burns McClellan
lroth@burnsmc.com
212.213.0006
OR
Media on behalf of Daré Bioscience, Inc.:
Jake Robison
Evoke Canale
jake.robison@evokegroup.com
619.849.5383
Source: Daré Bioscience, Inc.
FAQ
What conferences is Daré Bioscience participating in February 2023?
When is the presentation by Daré Bioscience's CEO scheduled?
What is the focus of Daré Bioscience's product portfolio?
Where can I follow updates about Daré Bioscience?